ClinicalTrials.gg
TerminatedNCT04424641Updated Jul 25, 2023Results posted

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

A Phase 1/2 interventional study of GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4. in Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer and Esophageal Cancer, sponsored by Genmab. Terminated at 6 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-25.

Sponsored by Genmab · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Study was terminated due to MTD was reached

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 3,596 studies in Prostatic Neoplasms with a site in United States — 608 open to participants now, 977 under way, 101 of them phase 3. Prostatic Neoplasms · United States.

Enrollment
1,502nd of 3,023
48 · median 48
Started
2020
with 167 others
Phase 1/2
283 of 3,596
62 open now
Registered
2,545th of 3,596
by date

Among the 3,596 studies in Prostatic Neoplasms with a site in United States, this one is the 1,502nd largest by enrollment of the 3,023 interventional ones that give a count, is one of 168 that started in 2020, is one of 283 in phase 1/2, and was the 2,545th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

608 of the 3,596 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

603 more — sign in →

All 608 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,596 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of the trial is to evaluate the safety, determine the recommended Phase 2 dose (RP2D), and assess preliminary clinical activity of GEN1044 in patients with solid tumors.

Read the detailed description

The trial is an open-label, multi-center safety trial of GEN1044. The trial consists of two parts: a dose-escalation part (Phase 1) and an expansion part (Phase 2a). The expansion part of the trial will be initiated once the RP2D has been determined from Phase 1.

03

Conditions studied

  • Locally Advanced or Metastatic Solid Tumor(s)
  • Prostate Cancer
  • Esophageal Cancer
  • Triple Negative Breast Cancer (TNBC)
  • Squamous Cell Carcinoma of Head and Neck (SCCHN)
  • Non-small Cell Lung Cancer (NSCLC)
  • Bladder Cancer
  • Uterine Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Dose-escalation part:

  • Patient with locally advanced or solid tumor(s) (excluding patients with primary central nervous system [CNS] tumors), who has experienced disease progression while on standard therapy or is intolerant of, or not eligible for, standard therapy.

Expansion part:

  • Must have an advanced or metastatic, confirmed diagnosis of one of the following tumors: Uterine Cancer, Prostate Cancer, Esophageal Cancer, TNBC, SCCHN, NSCLC (both adenocarcinoma [ACC] and squamous cell carcinoma [SCC], Bladder Cancer.

Both parts:

  • Must sign an form (ICF) indicating that he or she understands the purpose of, and procedures required for the trial, and is willing to participate in the trial prior to any trial related assessments or procedures.
  • Must have according to response assessment criteria relevant to the tumor type.
  • Must have an Performance Status (ECOG-PS) score of 0-1 at Screening and on C1D1.
  • A woman of must agree to use adequate during the trial and for 4 months after the last GEN1044 administration. Adequate contraception is defined as highly effective methods of contraception.

Key Exclusion Criteria (both parts):

  1. Has an uncontrolled intercurrent illness, including but not limited to:

    1. Ongoing or active infection requiring intravenous treatment with anti-infective therapy
    2. Symptomatic congestive heart failure (grade III or IV as classified by the ), unstable angina pectoris or cardiac arrhythmia.
    3. Uncontrolled hypertension defined as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg, despite optimal medical management.
    4. Ongoing or recent evidence of significant disease. Patients with a history of grade 3 or higher immune-related adverse events that led to treatment discontinuation.
    5. Patients with a prior history of myositis, Guillain-Barré syndrome, or myasthenia gravis of any grade.
    6. History of chronic liver disease or evidence of hepatic cirrhosis.
    7. History of non-infectious pneumonitis that has required , or currently has pneumonitis.
    8. History of organ allograft (except for corneal transplant) or or allogeneic bone marrow transplant, or stem cell rescue within 3 months prior to the first dose of GEN1044.
    9. Serious, non-healing wound, skin ulcer (of any grade), or bone fracture.
  2. Any history of intracerebral arteriovenous malformation, cerebral aneurysm, new or symptomatic or stroke.
  3. Prior therapy:

    Radiotherapy: Radiotherapy within 14 days prior to first GEN1044 administration. Palliative radiotherapy will be allowed.

  4. Treatment with an anti-cancer agent (within 28 days or after at least 5 half-lives of the drug, whichever is shorter), prior to GEN1044 administration. Toxicities from previous anti-cancer therapies that have not resolved.
  5. Has a history of ≥ grade 2 cytokine release syndrome (CRS) with other CD3-based bispecifics, or a history of ≥ grade 3 allergic reactions to monoclonal antibody therapy as well as known or has known allergies, , or intolerance to GEN1044 or its .
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    GEN1044

    Biological: GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.

Interventions

  • BiologicalGEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.

    Drug page: Immunoglobulin G

    GEN1044 will be administered intravenously in cycles of 21 days.

    Also known as: DuoBody®-CD3x5T4

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicities (DLTs)

    The DLT was defined as Grade (G) \>= 3 cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome; any G3 or 4 hematologic and non-hematologic toxicity (with exceptions defined by the protocol); laboratory abnormality that required clinically significant medical intervention, led to hospitalization, persisted for \>1 week, or resulted in a drug-induced liver injury; G3 or 4 febrile neutropenia; liver toxicity defined by Hy's law; any treatment-related toxicity that caused treatment discontinuation during Cycle 1; or any G5 toxicity.

    Time frame: From Day 1 to Day 21 of first cycle

  2. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) is defined as an AE that meets one of the following criteria: fatal or life-threatening; results in persistent or significant disability/incapacity; constitutes a congenital anomaly/birth defect; medically significant (an event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the outcomes listed above \[medical and scientific judgment must be exercised in deciding whether an AE is 'medically significant'\]); required inpatient hospitalization or prolongation of existing hospitalization. A TEAE is defined as an AE occurring or worsening between the first dose of GEN1044 and 30 days after the last dose received.

    Time frame: Day 1 through Day 263 (corresponding to maximum observed duration)

  3. Number of Participants With Abnormal Laboratory Values

    Number of participants with laboratory values of Grade \>= 3 by NCI-CTCAE v5.0 are reported. The NCI-CTCAE is a descriptive terminology that is used for gradings (Grade 1-5) of Adverse Events (AEs) and of laboratory values; the latter being summarized here. This table reports laboratory values graded only on the numerical value of the reported parameter and is therefore not graded by symptoms or signs. The abnormal laboratory values assessed by the investigator as being AEs are reported also in the AE table. In case a participant reported multiple severity grades for a laboratory value, only the maximum grade was used.

    Time frame: Day 1 through Day 263 (corresponding to maximum observed duration)

Secondary outcomes

  1. Number of Participants With Complete Response (CR) or Partial Response (PR)

    The radiological evaluation based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) was performed by investigator using computed tomography (CT) scan/ magnetic resonance imaging (MRI) scan/ positron emission tomography (PET) scan. The CR was defined as disappearance of all target and non-target lesions and all pathological lymph nodes must have decreased to \< 10 mm in short axis. The PR was defined as at least a 30% decrease in the sum of the longest diameters of target lesions taking as reference the baseline sum of longest diameters.

    Time frame: Day 1 through Day 233

  2. Number of Participants With Antidrug Antibodies (ADAs) Positive to GEN1044

    The detection and titer characterization of ADAs was performed using validated, specific, and sensitive electrochemiluminescence immunoassay (ECLIA) methods. Number of participants with ADA positive post baseline to GEN1044 are reported.

    Time frame: Day 1 through Day 263 (predose on Day 1 of Cycles 1, 2, 3, 5, 7, and then on Day 1 of every 4 cycles thereafter, end of treatment [EOT], and 30 days after last study drug)

07

Results

Posted Feb 1, 2023
Limitations and caveats
Upon review and evaluation of the overall safety profile and safety signals of GEN1044 during the dose-escalation part, the Safety Committee decided to stop further enrollment and the Sponsor decided to stop the compound development. Hence, the expansion part of the trial was never initiated, and while a majority of the pharmacokinetic (PK) samples from the dose-escalation part were quantified, the PK parameters were not calculated due to termination of the trial.

Participant flow

Participant flow — Overall Study
MilestoneGEN1044 Doses 0.3/3/3 mgGEN1044 Doses 1/3/10 mgGEN1044 Doses 1/3/30 mgGEN1044 Doses 1/5/30 mgGEN1044 Doses 1/10/30 mgGEN1044 Doses 1/5/37.5 mgGEN1044 Doses 1/5/45 mgGEN1044 Doses 1/3/60 mg
Started14776246
Completed00000000
Not completed14776246
Withdrew: Death12303012
Withdrew: Sponsor decision02372234
Withdrew: Withdrawal by subject00001000
Withdrew: Other00100000

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicities (DLTs)

The DLT was defined as Grade (G) \>= 3 cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome; any G3 or 4 hematologic and non-hematologic toxicity (with exceptions defined by the protocol); laboratory abnormality that required clinically significant medical intervention, led to hospitalization, persisted for \>1 week, or resulted in a drug-induced liver injury; G3 or 4 febrile neutropenia; liver toxicity defined by Hy's law; any treatment-related toxicity that caused treatment discontinuation during Cycle 1; or any G5 toxicity.

Time frame:
From Day 1 to Day 21 of first cycle
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities (DLTs)
ParticipantsGEN1044 Doses 0.3/3/3 mgGEN1044 Doses 1/3/10 mgGEN1044 Doses 1/3/30 mgGEN1044 Doses 1/5/30 mgGEN1044 Doses 1/10/30 mgGEN1044 Doses 1/5/37.5 mgGEN1044 Doses 1/5/45 mgGEN1044 Doses 1/3/60 mg
Number of Participants With Dose Limiting Toxicities (DLTs)00001—33
PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) is defined as an AE that meets one of the following criteria: fatal or life-threatening; results in persistent or significant disability/incapacity; constitutes a congenital anomaly/birth defect; medically significant (an event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the outcomes listed above \[medical and scientific judgment must be exercised in deciding whether an AE is 'medically significant'\]); required inpatient hospitalization or prolongation of existing hospitalization. A TEAE is defined as an AE occurring or worsening between the first dose of GEN1044 and 30 days after the last dose received.

Time frame:
Day 1 through Day 263 (corresponding to maximum observed duration)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
ParticipantsGEN1044 Doses 0.3/3/3 mgGEN1044 Doses 1/3/10 mgGEN1044 Doses 1/3/30 mgGEN1044 Doses 1/5/30 mgGEN1044 Doses 1/10/30 mgGEN1044 Doses 1/5/37.5 mgGEN1044 Doses 1/5/45 mgGEN1044 Doses 1/3/60 mg
Any TEAE14776246
Any TESAE11354135
PrimaryNumber of Participants With Abnormal Laboratory Values

Number of participants with laboratory values of Grade \>= 3 by NCI-CTCAE v5.0 are reported. The NCI-CTCAE is a descriptive terminology that is used for gradings (Grade 1-5) of Adverse Events (AEs) and of laboratory values; the latter being summarized here. This table reports laboratory values graded only on the numerical value of the reported parameter and is therefore not graded by symptoms or signs. The abnormal laboratory values assessed by the investigator as being AEs are reported also in the AE table. In case a participant reported multiple severity grades for a laboratory value, only the maximum grade was used.

Time frame:
Day 1 through Day 263 (corresponding to maximum observed duration)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Laboratory Values
ParticipantsGEN1044 Doses 0.3/3/3 mgGEN1044 Doses 1/3/10 mgGEN1044 Doses 1/3/30 mgGEN1044 Doses 1/5/30 mgGEN1044 Doses 1/10/30 mgGEN1044 Doses 1/5/37.5 mgGEN1044 Doses 1/5/45 mgGEN1044 Doses 1/3/60 mg
Lymphocyte count decreased14745226
Lipase increased00110122
Serum amylase increased00111111
Hypomagnesemia00001020
Creatinine increased00010010
Anemia01000001
Hypokalemia01000010
Hypoalbuminemia00001000
Blood bilirubin increased00100000
Gamma-glutamyl transferase increased10000000
Hypermagnesemia00000001
Platelet count decreased00000001
SecondaryNumber of Participants With Complete Response (CR) or Partial Response (PR)

The radiological evaluation based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) was performed by investigator using computed tomography (CT) scan/ magnetic resonance imaging (MRI) scan/ positron emission tomography (PET) scan. The CR was defined as disappearance of all target and non-target lesions and all pathological lymph nodes must have decreased to \< 10 mm in short axis. The PR was defined as at least a 30% decrease in the sum of the longest diameters of target lesions taking as reference the baseline sum of longest diameters.

Time frame:
Day 1 through Day 233
Reported as:
Count of participants · Participants
Number of Participants With Complete Response (CR) or Partial Response (PR)
ParticipantsGEN1044 Doses 0.3/3/3 mgGEN1044 Doses 1/3/10 mgGEN1044 Doses 1/3/30 mgGEN1044 Doses 1/5/30 mgGEN1044 Doses 1/10/30 mgGEN1044 Doses 1/5/37.5 mgGEN1044 Doses 1/5/45 mgGEN1044 Doses 1/3/60 mg
Complete response00000000
Partial response00000001
SecondaryNumber of Participants With Antidrug Antibodies (ADAs) Positive to GEN1044

The detection and titer characterization of ADAs was performed using validated, specific, and sensitive electrochemiluminescence immunoassay (ECLIA) methods. Number of participants with ADA positive post baseline to GEN1044 are reported.

Time frame:
Day 1 through Day 263 (predose on Day 1 of Cycles 1, 2, 3, 5, 7, and then on Day 1 of every 4 cycles thereafter, end of treatment [EOT], and 30 days after last study drug)
Reported as:
Count of participants · Participants
Number of Participants With Antidrug Antibodies (ADAs) Positive to GEN1044
ParticipantsGEN1044 Doses 0.3/3/3 mgGEN1044 Doses 1/3/10 mgGEN1044 Doses 1/3/30 mgGEN1044 Doses 1/5/30 mgGEN1044 Doses 1/10/30 mgGEN1044 Doses 1/5/37.5 mgGEN1044 Doses 1/5/45 mgGEN1044 Doses 1/3/60 mg
Number of Participants With Antidrug Antibodies (ADAs) Positive to GEN104403210011

Adverse events

Collected over For AEs: Day 1 through Day 263 (corresponding to maximum observed duration); For All-cause mortality: From date of inform consent form through Day 263 (corresponding to maximum observed duration). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GEN1044 Doses 0.3/3/3 mg1/1 (100%)1/1 (100%)1/1 (100%)
GEN1044 Doses 1/3/10 mg2/4 (50%)1/4 (25%)4/4 (100%)
GEN1044 Doses 1/3/30 mg3/7 (42.9%)3/7 (42.9%)7/7 (100%)
GEN1044 Doses 1/5/30 mg0/7 (0%)5/7 (71.4%)7/7 (100%)
GEN1044 Doses 1/10/30 mg4/6 (66.7%)4/6 (66.7%)6/6 (100%)
GEN1044 Doses 1/5/37.5 mg0/2 (0%)1/2 (50%)2/2 (100%)
GEN1044 Doses 1/5/45 mg1/4 (25%)3/4 (75%)4/4 (100%)
GEN1044 Doses 1/3/60 mg2/6 (33.3%)5/6 (83.3%)5/6 (83.3%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventGEN1044 Doses 0.3/3/3 mgGEN1044 Doses 1/3/10 mgGEN1044 Doses 1/3/30 mgGEN1044 Doses 1/5/30 mgGEN1044 Doses 1/10/30 mgGEN1044 Doses 1/5/37.5 mgGEN1044 Doses 1/5/45 mgGEN1044 Doses 1/3/60 mg
Tumour Associated FeverNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/10/40/70/70/60/20/40/6
DiarrhoeaGastrointestinal disorders0/10/40/72/71/61/20/41/6
Cytokine Release SyndromeImmune system disorders0/10/42/73/73/60/22/43/6
PneumonitisRespiratory, thoracic and mediastinal disorders0/10/41/70/71/60/21/42/6
VertigoEar and labyrinth disorders0/10/40/70/70/60/21/40/6
General Physical Health DeteriorationGeneral disorders0/11/40/70/71/60/20/40/6
DizzinessNervous system disorders0/10/40/70/70/60/21/41/6
Pleural EffusionRespiratory, thoracic and mediastinal disorders0/10/41/70/70/60/21/40/6
FatigueGeneral disorders0/10/40/70/71/60/20/41/6
Platelet Count DecreasedInvestigations0/10/40/70/70/60/20/41/6
Most frequent other events
Showing 10 of 89
Most frequent other events
EventGEN1044 Doses 0.3/3/3 mgGEN1044 Doses 1/3/10 mgGEN1044 Doses 1/3/30 mgGEN1044 Doses 1/5/30 mgGEN1044 Doses 1/10/30 mgGEN1044 Doses 1/5/37.5 mgGEN1044 Doses 1/5/45 mgGEN1044 Doses 1/3/60 mg
ConstipationGastrointestinal disorders1/11/42/70/73/60/20/41/6
DiarrhoeaGastrointestinal disorders1/14/46/74/75/61/24/44/6
DyspepsiaGastrointestinal disorders1/10/41/70/70/60/20/42/6
NauseaGastrointestinal disorders1/13/45/74/74/61/23/45/6
VomitingGastrointestinal disorders0/13/45/72/75/60/24/44/6
FatigueGeneral disorders0/14/44/70/74/61/22/41/6
Cytokine Release SyndromeImmune system disorders1/13/42/73/73/62/22/44/6
HyponatraemiaMetabolism and nutrition disorders1/10/40/70/70/60/20/40/6
Tumour PainNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/10/40/70/70/60/20/40/6
HeadacheNervous system disorders1/11/40/70/70/61/21/42/6

Baseline characteristics

Full analysis set included all participants who received at least 1 dose of study drug. Participants were classified according to the assigned dose level cohort.

Age, Continuous
Age, Continuous(Years)GEN1044 Doses 0.3/3/3 mgGEN1044 Doses 1/3/10 mgGEN1044 Doses 1/3/30 mgGEN1044 Doses 1/5/30 mgGEN1044 Doses 1/10/30 mgGEN1044 Doses 1/5/37.5 mgGEN1044 Doses 1/5/45 mgGEN1044 Doses 1/3/60 mgTotal
Mean51.0 ± NA61.3 ± 12.8960.4 ± 11.2159.3 ± 8.1862.3 ± 5.7952.0 ± 8.4955.8 ± 15.7154.2 ± 15.2958.4 ± 10.85
Sex: Female, Male
Sex: Female, Male(Participants)GEN1044 Doses 0.3/3/3 mgGEN1044 Doses 1/3/10 mgGEN1044 Doses 1/3/30 mgGEN1044 Doses 1/5/30 mgGEN1044 Doses 1/10/30 mgGEN1044 Doses 1/5/37.5 mgGEN1044 Doses 1/5/45 mgGEN1044 Doses 1/3/60 mgTotal
Female1233412319
Male0244212318
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)GEN1044 Doses 0.3/3/3 mgGEN1044 Doses 1/3/10 mgGEN1044 Doses 1/3/30 mgGEN1044 Doses 1/5/30 mgGEN1044 Doses 1/10/30 mgGEN1044 Doses 1/5/37.5 mgGEN1044 Doses 1/5/45 mgGEN1044 Doses 1/3/60 mgTotal
Hispanic or Latino000000000
Not Hispanic or Latino1025100211
Unknown or Not Reported0452524426
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GEN1044 Doses 0.3/3/3 mgGEN1044 Doses 1/3/10 mgGEN1044 Doses 1/3/30 mgGEN1044 Doses 1/5/30 mgGEN1044 Doses 1/10/30 mgGEN1044 Doses 1/5/37.5 mgGEN1044 Doses 1/5/45 mgGEN1044 Doses 1/3/60 mgTotal
American Indian or Alaska Native000000000
Asian000000000
Native Hawaiian or Other Pacific Islander000000000
Black or African American000000000
White1465624533
More than one race000000000
Unknown or Not Reported001200014
08

Study locations

6 sites
  • Tennesse Oncology, PLLC - Nashville
    Nashville, Tennessee 37203, United States
  • MD Anderson Cancer Center
    Houston, Texas 77054, United States
  • Rigshospitalet (Copenhagen University Hospital)
    Copenhagen, 2100, Denmark
  • Chaim Sheba Medical Center
    Ramat Gan, 5265601, Israel
  • Hospital Universitari Vall d'Hebron
    Barcelona, 8035, Spain
  • Fundacion Jimenez Diaz
    Madrid, 28040, Spain
09

References and documents

Publications

  • Kemper K, Gielen E, Boross P, Houtkamp M, Plantinga TS, de Poot SA, Burm SM, Janmaat ML, Koopman LA, van den Brink EN, Rademaker R, Verzijl D, Engelberts PJ, Satijn D, Sasser AK, Breij EC. Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor models. Life Sci Alliance. 2022 Sep 8;5(11):e202201481. doi: 10.26508/lsa.202201481. Print 2022 Nov. PubMed 36271507 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Oct 2021, 15 months.

Results were first posted in Feb 2023, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2020
First posted
Jun 11, 2020
StartActual
Jul 15, 2020
Primary completionActual
Oct 29, 2021
CompletionActual
Oct 29, 2021
Results first posted
Feb 1, 2023
Last update
Jul 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04424641
Lead sponsor
Genmab
Collaborators
AbbVie
Responsible party
Sponsor
First posted
Jun 11, 2020
Start date
Jul 15, 2020
Primary completion
Oct 29, 2021
Completion
Oct 29, 2021
Results posted
Feb 1, 2023
Last update
Jul 25, 2023

Study contacts

Roberto Oliveri, MD
study director · Genmab

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulin G

Start the discussion